Incannex (IXHL) Healthcare announces that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea, OSA, on schedule as of 16 June 2025. This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July 2025, reinforcing confidence in the program’s momentum and execution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IXHL:
- Incannex Healthcare Announces Psychedelic Therapies Joint Venture
- Incannex forms joint venture with Mind Medicine Australia
- Incannex Healthcare Transfers Listing to Nasdaq Capital Market
- Incannex Healthcare Cancels Series A Warrants
- Incannex cancels all outstanding Series A warrants following ATM execution